TITLE

Pluristem's PLX-PAD Plans Boosted by $36M Offering

AUTHOR(S)
Boggs, Jennifer
PUB. DATE
January 2011
SOURCE
BioWorld Today;1/28/2011, Vol. 22 Issue 19, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers information on the public offering held by Pluristem Theraprutics Inc. to secure funding for its plans for a Phase II/III trial of placenta-derived cell therapy PLX-PAD for critical limb ischemia (CLI). The offering involved 11 million shares sold at 3.25 U.S. dollars each, representing a 22% discount. The transaction, which is estimated to reach 35.8 million U.S. dollars, will also give purchasers a warrant to buy 0.4 of a share.
ACCESSION #
58018973

 

Related Articles

  • PLURISTEM GETS DSMB APPROVAL FOR PLX-PAD FINAL DOSE LEVEL.  // Biotech Business;Apr2010, Vol. 23 Issue 4, p6 

    The article announces the approval received by Pluristem Therapeutics Inc. of Haifa, Israel from the Safety Monitoring Board to advance to the highest and final dose level with its placenta-derived cell therapy (PLX-PAD) trial in Europe for the treatment of critical limb ischemia (CLI). Dr. Hans...

  • Pluristem Raising $32M Publicly As PLX Pipeline Gains Attention. Boggs, Jennifer // BioWorld Today;9/17/2012, Vol. 23 Issue 180, p1 

    The article reports on the move of Pluristem Therapeutics to nearly double its cash position with a public offering in 2012. The Israeli company aims to raise 32 million U.S. dollars from the public offering by selling eight million units. The news lead to a decline in the price of the company's...

  • Financings Roundup.  // BioWorld Today;9/24/2008, Vol. 19 Issue 186, p5 

    The article reports that Pluristem Therapeutics Inc. of New York City has raised additional fundings of $1 million in September 2008. These new fundings will be used to support the development of their preclinical allogenic, placenta-derived cell therapy products. As reported, Pluristem sold...

  • PLURISTEM GETS INTERIM TOP-LINE RESULTS FROM PLX-PAD TRIALS.  // Worldwide Biotech;Jun2010, Vol. 22 Issue 6, p3 

    The article reports on the interim top-line results from the Phase I clinical trials of Pluristem Therapeutics Inc. in Haifa, Israel, in June 2010, which utilize the placenta-derived cell therapy product PLX-PAD for treating critical limb ischemia (CLI). The interim data showed that PLX-PAD is...

  • Financings Roundup.  // BioWorld Today;2/2/2009, Vol. 20 Issue 20, p7 

    The article reports that New York City-based Pluristem Therapeutics Inc. is raising $1.2 million through the sale of 1.03 million units. The offering consists of one restricted share of common stock priced at $1.16 and one five-year warrant to purchase a common share for $1.90. Pluristem is a...

  • Pluristem Raising $32M Publicly As PLX Pipeline Gains Attention. Boggs, Jennifer // BioWorld International;9/19/2012, Vol. 17 Issue 38, p4 

    The article reports on the 32 million dollars that was raised by Israeli firm Pluristem Therapeutics Inc. during its public offering in mid-September 2012. The company is pursuing several clinical trials, including the Phase II testing of PLX cells in Buerger's disease and muscle injury. The...

  • Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data. Boggs, Jennifer // BioWorld International;5/5/2010, Vol. 15 Issue 18, p5 

    The article deals with the preliminary Phase I data released by Pluristem Therapeutics Inc. for its placenta-derived cell therapy treatment PLX-PAD in critical limb ischemia in May 2010. Information on the Phase I trial results is presented. It discloses the company's negotiations for a Phase II...

  • Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data. Boggs, Jennifer // BioWorld Today;4/28/2010, Vol. 21 Issue 81, p1 

    This article reports on the plan of Pluristem Therapeutics Inc. to conduct Phase II testing with its placenta-derived cell therapy treatment PLX-PAD in critical limb ischemia. The Israeli company announced the plan after reporting positive results from two Phase I trials of the treatment,...

  • Financings Roundup.  // BioWorld Today;3/7/2008, Vol. 19 Issue 46, p5 

    The article reports on an estimated $4.7 million in funds that is expected to be raised by Epicept Corp. The funds will be raised from a public offering of stock and warrants. Epicept has decided to price about 5.4 millin shares of common stock at 92.3 cents per share together with five-year...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics